Spyre Therapeutics, Inc.
Healthcare · EUR · F
Price
€63.596
Cap
€6.52B
Earnings
—
30d Trend
+5.0%
BRAIN47 SIGNAL
Raw weighted: 51×Macro 0.99 (−1%)=50
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
6-9 month momentum thesis — strong trend with confirmation
BRAIN47'S ASSESSMENT
I rate Spyre Therapeutics, Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 88/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
DETAILED ANALYSIS
6-9 month momentum thesis — strong trend with confirmation. Momentum (88) and Technical (55) are the primary strengths. I note that quality is the weakest area at 22/100 — this warrants monitoring. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.